Approvals· August 29, 2026 · 24 min read
Mimrylo for PV Erythrocytosis: 76.9% Week 20-32 Response and Platelet Rises
By Ran Chen#FDA Approval#Hematology#Coverage Access
Topic
Hematology
Hematology therapies, oncology-adjacent access, evidence standards, buy-and-bill dynamics, and payer criteria.
Approvals· August 27, 2026 · 20 min read
Imaavy's wAIHA Approval Is a Steroid-Gated, q4w Indication: J9256 Does Not Auto-Cover It
Approvals· August 23, 2026 · 18 min read
Besremi's August 30 ET PDUFA: Second-Line vs Anagrelide, Not Hydroxyurea
By Ran Chen#PDUFA Date#FDA Approval#Orange Book
Specialty· August 14, 2026 · 24 min read
Multiple Myeloma Treatment Access Landscape: Generic Revlimid, Zenbexus, & Darzalex
Specialty· August 11, 2026 · 17 min read
Myelofibrosis Treatment Access Landscape: Jakafi, Vonjo, & Selinexor
By Ran Chen#Hematology#JAK Inhibitor#Specialty Pharmacy
Pipeline· July 23, 2026 · 21 min read
Bispecific Antibody & T-Cell Engager Clinical Trials by the Numbers (2026)
Specialty· July 11, 2026 · 16 min read
Hemophilia Access 2026: Prophylaxis and Gene Therapy Post-Roctavian
By Ran Chen#Gene Therapy#Hematology#Payer Coverage
Evidence· July 10, 2026 · 17 min read
Anticoagulant Adverse Events in FAERS: 244,000 Reports and Bleeding/HIT Profiles
Pipeline· June 2, 2026 · 10 min read
Orca-T allogeneic cell therapy PDUFA preview: access implications for AML, ALL, and MDS
By Ran Chen#PDUFA Date#FDA Approval#Hematology